New drug combination for relapsed NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of NKTCL, a type of lymphoma that often affects the nose or sinuses.
- You must have had at least one prior treatment that included the drug asparaginase.
- You must be between 14 and 75 years old.
- You must have at least one measurable area of disease (a tumor that can be seen on scans).
- You should be generally active (able to do light work or be up and about) and have adequate organ function.
- You must not have an active autoimmune disease that required treatment in the last 2 years.
- You must not have active infections, significant heart problems, or a history of other cancers in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three treatments for a rare type of lymphoma called NKTCL that has come back or not responded to prior therapy. The treatments include a pill (selinexor), an immune-boosting drug (anti-PD-1 antibody), and a chemotherapy combination (P-GemOx). The goal is to see if this combination can help control the lymphoma and improve outcomes.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Hear when a new Lymphoma, Extranodal NK-T-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.